Stock Locations

New Jersey, USA
Czech Republic, EU
Mumbai, India

* Stock subject to availability.

Documentation

Download MSDS

Download Sample COA

Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.

82717-96-2Enalapril EP Impurity B

● In Stock

Catalogue No.:	VL1360002
CAS No.:	82717-96-2
Mol. Formula:	C15H21NO4
Mol. Weight:	279.33 g/mol

Request a quote

Add to RFQ list

Additional information on CAS 82717-96-2

Parent drug

Enalapril / Trandolapril/ Ramipril/ Quinapril / Spirapril/ Moexipril/ Enalaprilat

IUPAC Name

(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]propanoic acid

Smiles

C[C@@]([H])(C(O)=O)N[C@]([H])(C(OCC)=O)CCC1=CC=CC=C1

InChI

InChI=1S/C15H21NO4/c1-3-20-15(19)13(16-11(2)14(17)18)10-9-12-7-5-4-6-8-12/h4-8,11,13,16H,3,9-10H2,1-2H3,(H,17,18)/t11?,13-/m0/s1

Pharmacopeial Synonyms

Enalaprilat EP Impurity F/Ramipril EP Impurity F/Quinapril EP Impurity B/ Spirapril EP Impurity C/Moexipril Related Compound F

Synonyms

Benzenebutanoic acid ,N-[(S)-1-Ethoxycarbonyl-3-phenylpropyl]-L-alanine;N-[1(S)-Ethoxycarbonyl-3-phenylpropyl]-L-alanine

Pharmacopoeial Synonyms

Enalaprilat EP Impurity F/Ramipril EP Impurity F/Quinapril EP Impurity B/ Spirapril EP Impurity C/Moexipril Related Compound F

Other Synonyms

(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]propanoic Acid; Benzenebutanoic acid ,N-[(S)-1-Ethoxycarbonyl-3-phenylpropyl]-L-alanine;N-[1(S)-Ethoxycarbonyl-3-phenylpropyl]-L-alanine

Shipping Condition

Ambient Temperature

Characterization Data (Included)

HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, and Structure Elucidation Report (SER).

Additional Characterization Data

QNMR, D2O Exchange, 13C NMR, 13C APT, COSY NMR, NOESY NMR, 15N NMR, HSQC NMR, HMQC NMR, and HMBC NMR. These are available upon request and may be free or subject to additional charges.

Description

CAS 82717-96-2 corresponds to a peptide-like ACE inhibitor impurity of formula C15H21NO4 and molecular weight 279.33 g/mol, represented across several enalapril, trandolapril, ramipril, quinapril, spirapril, moexipril, and enalaprilat impurity designations. Structurally, it is consistent with a hydrolysis or side-chain cleavage product arising during synthesis or storage of ester prodrugs and their active diacid metabolites. The compound is not a nitrosamine, but its relatedness to process and degradation impurities places it within impurity profiling expectations under ICH Q3A/Q3B. Trace determination typically requires LC-MS/MS, high-resolution LC-HRMS, and orthogonal HPLC-UV methods, with confirmatory LC-MS fragmentation for assignment.

References

“Davies, Richard O., et al. “Enalapril Worldwide Experience.” The American Journal of Medicine, vol. 77, no. 2, Aug. 1984, pp. 23–35, https://doi.org/10.1016/s0002-9343(84)80055-8. ?Todd, Peter A., and Karen L. Goa. “Enalapril.” Drugs, vol. 43, no. 3, Mar. 1992, pp. 346–81, https://doi.org/10.2165/00003495-199243030-00005. ?”